PT  - JOURNAL ARTICLE
AU  - Shea J Andrews
AU  - Alison Goate
TI  - Mendelian randomization indicates that TNF is not causally associated with Alzheimer’s disease
AID  - 10.1101/673749
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 673749
4099  - http://biorxiv.org/content/early/2019/06/19/673749.short
4100  - http://biorxiv.org/content/early/2019/06/19/673749.full
AB  - INTRODUCTION Epidemiological research has suggested that inhibition of tumor necrosis factor (TNF)-α in patients with rheumatoid arthritis (RA) reduces the overall risk of Alzheimer’s disease (AD). TNF-α antagonists have been suggested as a potential treatment for AD.METHODS We used a two-sample Mendelian randomization design to examine the causal relationship between blood TNF expression, serum TNF-α levels, and RA on AD risk.RESULTS Our results do not support a causal relationship between TNF expression, serum TNF-α levels or RA on AD risk.DISCUSSION These results suggest that TNF-α antagonists are unlikely to reduce the risk of AD.